Cochrane for Clinicians
Putting Evidence into Practice
Risk of Venous Thromboembolism with Use of Combined Oral Contraceptives
Am Fam Physician. 2015 Mar 1;91(5):287-288.
Author disclosure: No relevant financial affiliations.
Which combined oral contraceptives carry the greatest risk of venous thromboembolism (VTE)?
All combined oral contraceptives increase VTE risk. The risk is greater for those containing desogestrel, drospirenone, gestodene (not available in the United States), and cyproterone acetate (not available in the United States) when compared with levonorgestrel. All combined oral contraceptives are effective in preventing pregnancy. (Strength of Recommendation: B, based on inconsistent or limited-quality patient-oriented evidence.)
The first combined oral contraceptives debuted in 1960 and are now used by 17% of women 15 to 44 years of age. In the United States, more women use combined oral contraceptives than any other contraceptive method.1 However, studies have demonstrated an up to fourfold increase in the risk of VTE among combined oral contraceptive users compared with nonusers (pregnancy carries a slightly greater than fourfold risk).2,3 Over time, the hormone formulations and dosages of combined oral contraceptives have changed in an effort to decrease thrombogenic risk. The authors of this review looked at studies featuring multiple combined oral contraceptive formulations and dosages to determine the relative risk associated with each.
This Cochrane review included nine cohort and 17 case-control studies. The authors found no pertinent randomized controlled trials. Only five studies objectively confirmed VTE in all study patients, raising concern that ascertainment bias influenced the outcomes of the other studies. The absolute risk of VTE in nonusers was 0.19 to 0.37 per 1,000 woman-years. The risk of VTE with combined oral contraceptive use (15 studies) was 3.5 times greater than with nonuse (95% confidence interval [CI], 2.9 to 4.3).
Compared with that of nonusers, the risk of VTE was 3.2 times greater (95% CI, 2.0 to 5.1) with first-generation progestins, 2.8 times greater (95% CI, 2.0 to 4.1) with second-generation progestins, and 3.8 times greater (95% CI, 2.7 to 5.4) with third-generation progestins. This corresponds to absolute risk increases of 0.61 to 1.18 per 1,000 woman-years for first-generation progestins, 0.55 to 1.04 per 1,000 woman-years for second-generation progestins, and 0.72 to 1.41 per 1,000 woman-years for third-generation progestins. Risk of VTE was similar among the third- and fourth-generation progestins desogestrel, drospirenone, gestodene, and cyproterone acetate, each of which carried a risk of VTE that was 50% to 80% higher than that associated with the second-generation progestin levonorgestrel.
The Centers for Disease Control and Prevention (CDC) recommends against combined oral contraceptive use in those who smoke more than 15 cigarettes per day, who have a blood pressure equal to or greater than 160 mm Hg systolic or 100 mm Hg diastolic, or who have multiple risk factors for or a history of vascular disease. Likewise, the CDC strongly recommends against the use of combined oral contraceptives in those who have a history of VTE or known thrombophilia.4
All women should be counseled on the risk of VTE with combined oral contraceptive use vs. the risk of VTE in pregnancy (1.4%; 95% CI, 1.0% to 1.8%).5 As much as possible, physicians should try to use lower-dose hormone formulations to decrease the risk of VTE. Based on this review, levonorgestrel has a lower risk than desogestrel, drospirenone, gestodene, or cyproterone acetate.
The practice recommendations in this activity are available at http://summaries.cochrane.org/CD010813.
The views expressed here are those of the author and do not necessarily reflect those of the U.S. Army or the Department of Defense.
de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;(3):CD010813.
REFERENCESshow all references
1. Hall KS, Trussell J. Types of combined oral contraceptives used by US women. Contraception. 2012;86(6):659–665....
2. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346(8990):1575–1582.
3. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):697–706.
4. Centers for Disease Control and Prevention (CDC). U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep. 2010;59(RR-4):1–86.
5. Meng K, Hu X, Peng X, Zhang Z. Incidence of venous thromboembolism during pregnancy and the puerperium: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2014 May 7:1–9. [Epub ahead of print] http://informahealthcare.com/doi/abs/10.3109/14767058.2014.913130. Accessed December 23, 2014.
Copyright © 2015 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Mar 15, 2017
Access the latest issue of American Family Physician